Methylphenidate has positive hypocholesterolemic and hypotriglyceridemic effects: New data

Journal of Clinical Pharmacology

Volumn 49, Issue 7, 2009, Pages 848-851

  Charach, Gideon ^a,b   Kaysar, Nehemia ^a   Grosskopf, Itamar ^a   Rabinovich, Alexander ^a   Weintraub, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Atherosclerosis; LDL cholesterol; Lipids; Lipoprotein (a); Methylphenidate; Total cholesterol

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPHENIDATE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD SAMPLING; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; APOLIPOPROTEINS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHOLESTEROL; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; METHYLPHENIDATE; TRIGLYCERIDES;

EID: 67650475916     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009336736     Document Type: Article

References (20)

1. Botton J., Heude B., Kettaneh A., et al. FLVS Study Group. Cardiovascular risk factor levels and their relationships with overweight and fat distribution in children: the Fleurbaix Laventie Ville Sante 2 study. Metabolism. 2007 ; 56: 614 622.
2. Yang P., Swann A., Dafny N. Valproate prevents the induction and expression of MK 801 sensitization. Brain Res. 2002 ; 954: 151 159.
3. Papacostas S. Oxcarbazepine versus carbamazepine treatment and induction of lipid abnormalities. J Clin Neurol. 2000 ; 15: 138 140.
4. Yilmaz E., Dosan Y., Gurgoze MK, Gungor S. Serum lipid changes during anticonvulsive treatment, serum lipids in epilep tic children. Acta Neurol Belg. 2001 ; 101: 217 220.
5. Sonmez F., Demir E., Orem A., et al. Effects of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. Clin Neurol. 2006 ; 21: 70 74.
6. Ruetsch O., Viala A., Bardou H., Martin P., Vacheron M. Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management. Encephale. 2005 ; 31: 507 516.
7. Keam S., Walker M. Therapies for narcolepsy with or without cataplexy: evidence based review. Curr Opin Neurol. 2007 ; 20: 699 703.
8. Gerardin P., Cohen D., Mazet P., Flament M. Drug treatment of conduct disorder in young people. Eur Neuropsychopharmacol. 2002 ; 12: 361 370.
9. Kabara JJ Brain cholesterol XVIII: effect of methylphenidate (Ritalin) on [U 14C] glucose and [2 3H] acetate incorporation. Proc Soc Epidemiol Biol Med. 1975 ; 150: 525 528.
10. Gonzalez de Dios J., Cardo E., Servera M. Methylphenidate in the treatment of attention deficit/hyperactivity disorder: are we achiev ing an adequate clinical practice? Rev Neurol. 2006 ; 43: 705 714.
11. Samuels JA, Eranco K., Wan F., Sorof JM Effect of stimulants on 24 ambulatory blood pressure in children with ADHD. Ped Nephrol. 2006 ; 21: 92 95.
12. Satterfield JH, Scell AM, Barb SD Potential risk of prolonged administration of stimulant medication for hyperactive children. Dev Behav Pediatr. 1980 ; 1 (3). 102 107.
13. Gontkovsky SR, Nevel R., McDonald NB, Winkelman MH Decreased serum glucose levels after initiation of methylphenidate in a patient status post cerebellar tumour resection: a potential interaction with glipizide. Clin Drug Investig. 2007 ; 217: 719 725.
14. Vitiello B. Understanding the risk using medications for atten tion deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin North Am. 2008 ; 17: 459 474.
15. Langendijk PN, Wilde AA Medication for ADHD and the risk of cardiovascular mortality [in Dutch]. Ned Tijdschr Geneeskd. 2006 ; 150: 1713 1714.
16. Rapport MD, Moffitt C. Attention deficit/hyperactivity disor der and methylpenidate: a review of height/weight, cardiovascu lar, and somatic complaints side effects. Clin Psychol Rev. 2002 ; 22: 1107 1131.
17. Spivak B., Veref Y., Yoran Hegesh R., et al. The influence of three months of methylphenidate treatment on platelet poor bio genic amine levels in boys with attention deficit hyperactivity disorder. Hum Psychopharmacol. 2001 ; 16: 333 337.
18. Gidding S. Cardiovascular risk factors in adolescents. Curr Treat Options Cardiovasc Med. 2006 ; 8: 269 275.
19. Viles Gonzalez JF, Anand SX, Valdiviezo C., et al. Update in atherothrombotic disease. Mt Sinai J Med. 2004 ; 71: 197 208.
20. Rader D., Hobbs H. Disorders of lipoprotein metabolism. In Kasper L, Braunwald E, Fauci A, eds. Harrison's Principles of Internal Medicine. 16 th ed. New York, NY: McGraw -Hill ; 2005: 2286 2298.